繁體版 / 簡體版
 
NEWS ROOM
/ NEWS ROOM
2018-09-07
Fountain Biopharma Inc. Granted Taiwan Patent for Cancer stem cell culture platform

Fountain Biopharma Inc. announces a platform of in vitro co-culture system for cancer-associated fibroblasts and cancer cells was received patent from Taiwan Intellectual property office (TIPO).

Title of the patent is “CANCER-ASSOCIATED FIBROBLASTS IN MAINTAINING STEMNESS OF CANCER STEM CELLS”, patent No. I634209.

This platform is an in vitro co-culture system for cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for screening drugs capable of inhibiting cancer stem cells. Also disclosed a paracrine signaling  for maintaining  cancer stemness could use to predict the drug response rate and prognosis in the cancer patients.

In the future, we could use this platform to discover the novel cancer stem cell markers, therapeutic targets and mechanism.


模拟人生4 俱乐部赚钱 云南今天快乐十分走势图 快三游戏恐龙快打安卓 腾讯分分彩1个月赢40w 时时乐上海开奖结果时 福彩快乐10分玩法 排列五万百和值尾振幅走势 后二组选包胆怎么倍投 四肖期期准一必三肖 广东十一选五怎么玩才赚钱 陕西十一选五开奖号码